Daiichi Sankyo and Waiv partner for ADC biomarkers
Daiichi Sankyo has entered a collaboration with France-based Waiv, which aims to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) programme. Waiv will use its computational pathology platform to work with early phase data, …